Summary
Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K to announce its new five-year strategic plan, "Alnylam 2030." This plan outlines the company's vision and direction for the next five years, aiming to drive growth and innovation in the RNAi therapeutics space. In conjunction with the strategy, Alnylam provided preliminary unaudited financial results for the fourth quarter and full year 2025. The company anticipates approximately $995 million in global net product revenues for Q4 2025 and $2,987 million for the full year 2025, driven by its key products AMVUTTRA®, ONPATTRO®, GIVLAARI®, and OXLUMO®. Alnylam also offered initial product and pipeline goals for 2026, including combined net product revenue guidance.
Key Highlights
- 1Alnylam announced its new five-year strategic plan, "Alnylam 2030."
- 2Preliminary Q4 2025 global net product revenues are estimated at approximately $995 million.
- 3Preliminary full year 2025 global net product revenues are estimated at approximately $2,987 million.
- 4Key revenue drivers for 2025 include AMVUTTRA®, ONPATTRO®, GIVLAARI®, and OXLUMO®.
- 5The company provided initial product and pipeline goals for 2026.
- 6Full year 2026 combined net product revenue guidance has been issued.
Frequently Asked Questions
The company anticipates announcing its complete financial results in February 2026.
No, the preliminary selected financial results reported are unaudited and subject to adjustment.
The preliminary revenues are generated from AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran).
The "Alnylam 2030" strategy is the company's new five-year plan designed to guide its growth and innovation in the RNAi therapeutics sector.